Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELU NASDAQ:MBIO NASDAQ:TXMD NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$0.71-1.9%$1.02$0.67▼$4.35$21.04M0.48136,004 shs35,479 shsMBIOMustang Bio$0.74-7.3%$0.71$0.53▼$7.00$6.05M2.08323,704 shs45,724 shsTXMDTherapeuticsMD$2.20+20.9%$2.05$0.98▼$2.95$21.07M0.644,498 shs259,099 shsVYNEVYNE Therapeutics$0.65-2.5%$0.65$0.28▼$1.96$22.18M2122,711 shs82,649 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity-6.05%-26.95%-6.40%-40.43%-59.62%MBIOMustang Bio+8.28%+13.69%+21.24%-15.29%-37.66%TXMDTherapeuticsMD-2.15%-9.00%-6.67%-16.13%+51.67%VYNEVYNE Therapeutics+0.94%-0.03%+0.76%+12.45%-27.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$0.71-1.9%$1.02$0.67▼$4.35$21.04M0.48136,004 shs35,479 shsMBIOMustang Bio$0.74-7.3%$0.71$0.53▼$7.00$6.05M2.08323,704 shs45,724 shsTXMDTherapeuticsMD$2.20+20.9%$2.05$0.98▼$2.95$21.07M0.644,498 shs259,099 shsVYNEVYNE Therapeutics$0.65-2.5%$0.65$0.28▼$1.96$22.18M2122,711 shs82,649 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity-6.05%-26.95%-6.40%-40.43%-59.62%MBIOMustang Bio+8.28%+13.69%+21.24%-15.29%-37.66%TXMDTherapeuticsMD-2.15%-9.00%-6.67%-16.13%+51.67%VYNEVYNE Therapeutics+0.94%-0.03%+0.76%+12.45%-27.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 2.00Hold$6.00741.63% UpsideMBIOMustang Bio 1.00SellN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/AVYNEVYNE Therapeutics 1.75ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest MBIO, VYNE, TXMD, and CELU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026VYNEVYNE Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MBIOMustang Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/6/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$26.55M0.78N/AN/A($1.32) per share-0.54MBIOMustang BioN/AN/AN/AN/A$1.31 per shareN/ATXMDTherapeuticsMD$3.02M8.43$0.06 per share39.01$2.32 per share0.95VYNEVYNE Therapeutics$570K37.94N/AN/A$0.83 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)MBIOMustang Bio-$1.92M-$0.48N/AN/AN/AN/A-35.38%-16.36%8/18/2026 (Estimated)TXMDTherapeuticsMD-$570K$0.0636.67N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)VYNEVYNE Therapeutics-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%8/13/2026 (Estimated)Latest MBIO, VYNE, TXMD, and CELU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026VYNEVYNE Therapeutics-$0.18-$0.08+$0.10-$0.08$0.20 million$0.09 million5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 million5/5/2026Q1 2026MBIOMustang Bio-$140.00-$0.14+$139.86-$0.14N/AN/A4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 million3/30/2026Q4 2025TXMDTherapeuticsMD-$6.1250-$0.0530+$6.0720-$0.05$19.77 million$0.89 million3/19/2026Q4 2025MBIOMustang BioN/A-$0.08N/A-$0.0780N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularityN/A0.150.15MBIOMustang BioN/A2.122.12TXMDTherapeuticsMDN/A3.113.11VYNEVYNE TherapeuticsN/A20.8620.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%MBIOMustang Bio9.95%TXMDTherapeuticsMD30.74%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipCELUCelularity17.30%MBIOMustang Bio4.00%TXMDTherapeuticsMD1.70%VYNEVYNE Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22028.95 million23.94 millionOptionableMBIOMustang Bio1007.58 million7.27 millionNot OptionableTXMDTherapeuticsMD42011.57 million11.38 millionOptionableVYNEVYNE Therapeutics3033.35 million32.34 millionNot OptionableMBIO, VYNE, TXMD, and CELU HeadlinesRecent News About These CompaniesVYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04May 15, 2026 | msn.comShareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 18, 2025 | prnewswire.com3 penny stocks to watch now, 12/18/25December 18, 2025 | msn.comVYNE to merge with Yarrow in $200 million dealDecember 18, 2025 | thepharmaletter.comTRoundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow BioscienceDecember 17, 2025 | pharmexec.comP$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)December 17, 2025 | prnewswire.comVYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersDecember 17, 2025 | businesswire.comVYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks TranscriptDecember 17, 2025 | seekingalpha.comVyne Therapeutics stock soars after merger with Yarrow BioscienceDecember 17, 2025 | za.investing.comVyne Therapeutics, Yarrow Bioscience to MergeDecember 17, 2025 | marketwatch.comVyne Therapeutics shares surge on merger deal with Yarrow BioscienceDecember 17, 2025 | msn.comVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementDecember 17, 2025 | globenewswire.comVYNE Therapeutics Approves Director Elections and ProposalsDecember 12, 2025 | tipranks.comVYNE Therapeutics reports Q3 EPS (17c) vs (29c) last yearNovember 6, 2025 | msn.comVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesNovember 6, 2025 | zacks.comVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateNovember 6, 2025 | globenewswire.comIncyte scraps BET inhibitor against backdrop of safety concerns for the drug classOctober 28, 2025 | fiercebiotech.comFVYNE Therapeutics (VYNE) Price Target Decreased by 22.00% to 3.32October 1, 2025 | msn.comVYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBIO, VYNE, TXMD, and CELU Company DescriptionsCelularity NASDAQ:CELU$0.71 -0.01 (-1.91%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.68%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Mustang Bio NASDAQ:MBIO$0.74 -0.06 (-7.31%) As of 04:00 PM EasternMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.TherapeuticsMD NASDAQ:TXMD$2.20 +0.38 (+20.88%) As of 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.VYNE Therapeutics NASDAQ:VYNE$0.65 -0.02 (-2.47%) Closing price 04:00 PM EasternExtended Trading$0.65 +0.00 (+0.23%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
